Results 171 to 180 of about 5,874,294 (289)

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Structure-based screening and identification of a novel Aurora-A-targeting peptide with antiproliferative activity against prostate cancer cells. [PDF]

J Enzyme Inhib Med Chem
Huang BB, Jiang H, Hu Y, Ge JJ, Liu X.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Isolation and Characterisation of Alkaloids from Marine-Derived <i>Aspergillus fumigatus</i> SYPHU504 with Antiproliferative Activity. [PDF]

Mar Drugs
Zhang X, Yu Y, Liu K, Liu Y, Zhang H, Xiao J.   +5 more
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Design, synthesis and antiproliferative activity of pyridone derivatives as potent enhancer of zeste homologue 2/histone deacetylase dual inhibitors. [PDF]

RSC Adv
Tan Z, Ding J, Chen X, Qian L, Yu Q.
europepmc   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

Cancer Science, EarlyView.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota, Tokiyoshi Tanegashima, Takahiko Hajime, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto   +8 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Evidence of Antiproliferative Activity in the Liverwort <i>Isotachis serrulata</i> from Southern Ecuador. [PDF]

Molecules
Andrade JM, Benítez Á, González-Bakker A, Cartuche L, Padrón JM, Díaz-Marrero AR, Fernandez JJ.   +6 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source